Patent GB678427A successfully refreshed from Google Patents.
US20050178389A1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Disease indications for selective endobronchial lung region isolation
Assignee: Pulmonx Corp
•
Filing: 2005-01-26
•
Granted: —
•
Expires: 2025-01-26
Abstract
Abstract Disclosed are various disease indications and treatment methods that benefit from selective lung region isolation. A lung region is bronchially isolated by regulating the flow of fluid to and from the lung region, such as by implanting one or more bronchial isolation devices into one or more bronchial passageways that feed air to the lung region. The bronchial isolation devices can comprise, for example, one-way valves, two-way valves, occluders or blockers, ligating clips, glues, sealants, and sclerosing agents.
Inventors
- 👤 David Shaw
- 👤 John McCutcheon
- 👤 Antony Fields
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 04:07
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/02; A61F2/04; A61B; A61B17/00; A61B17/12; A61B17/12022; A61B17/12027; A61B17/12036; A61B17/12099; A61B17/12104; A61B17/12131; A61B17/12159; A61F2/24; A61F2/2476; A61B17/12168; A61B17/12172; A61F2/82; A61F2002/043
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
26 words
1 . A method of treating pulmonary hypertension in a human or mammal comprising blocking fluid flow in a bronchial passageway sufficiently to reduce pulmonary hypertension.
Claim 2
Dependent Claim
26 words
1 . A method of treating pulmonary hypertension in a human or mammal comprising blocking fluid flow in a bronchial passageway sufficiently to reduce pulmonary hypertension.
Claim 3
Dependent Claim
41 words
2 . The method of claim 1 , wherein blocking fluid flow in a bronchial passageway sufficiently to reduce pulmonary hypertension comprises delivering a therapeutically effective quantity of a fluid-blocking material to one or more bronchial passageways to reduce pulmonary hypertension.
Claim 4
Dependent Claim
39 words
3 . A method of treating pulmonary hypertension in a human or mammal comprising: assessing a level of pulmonary hypertension of a patient; and reducing fluid flow into a selected region of a lung until pulmonary hypertension is reduced.
Claim 5
Dependent Claim
39 words
3 . A method of treating pulmonary hypertension in a human or mammal comprising: assessing a level of pulmonary hypertension of a patient; and reducing fluid flow into a selected region of a lung until pulmonary hypertension is reduced.
Claim 6
Dependent Claim
39 words
4 . The method of claim 3 , wherein reducing fluid flow into a selected region of a lung until pulmonary hypertension is reduced comprises blocking fluid flow through a lung passageway until the level of pulmonary hypertension decreases.
Claim 7
Dependent Claim
41 words
5 . The method of claim 3 , wherein reducing fluid flow into a selected region of a lung until pulmonary hypertension is reduced comprises redirecting fluid flow away from a selected region of a lung until pulmonary hypertension is reduced.
Claim 8
Dependent Claim
54 words
6 . The method of claim 3 , wherein reducing fluid flow into a selected region of a lung until pulmonary hypertension is reduced comprises placing a blocking element in a bronchial passageway communicating with the lung region, the blocking element inhibiting fluid flow into the lung region without collapsing the target lung region.
Claim 9
Dependent Claim
48 words
7 . A method of reducing pulmonary hypertension in a patient comprising: assessing pulmonary function; comparing the pulmonary function to an eligibility threshold; and if pulmonary function is higher than the eligibility threshold, blocking fluid flow into a selected region of the lung; wherein pulmonary hypertension is reduced.
Claim 10
Dependent Claim
48 words
7 . A method of reducing pulmonary hypertension in a patient comprising: assessing pulmonary function; comparing the pulmonary function to an eligibility threshold; and if pulmonary function is higher than the eligibility threshold, blocking fluid flow into a selected region of the lung; wherein pulmonary hypertension is reduced.
Claim 11
Dependent Claim
63 words
8 . A method of improving lung function of a patient comprising: measuring a lung function indicator to obtain an initial value; comparing the initial value to a threshold value; and if the initial value is higher than the threshold value, blocking fluid flow into one or more regions of the lung sufficiently to raise the lung function indicator above the initial value.
Claim 12
Dependent Claim
63 words
8 . A method of improving lung function of a patient comprising: measuring a lung function indicator to obtain an initial value; comparing the initial value to a threshold value; and if the initial value is higher than the threshold value, blocking fluid flow into one or more regions of the lung sufficiently to raise the lung function indicator above the initial value.
Claim 13
Dependent Claim
60 words
9 . A method of treating low carbon monoxide diffusing capacity of a lung (DLCO) in a patient comprising: measuring an initial DLCO; comparing the initial DLCO to a threshold DLCO; and if the initial DLCO is higher than the threshold DLCO, blocking fluid flow into one or more regions of the lung sufficiently to achieve an increase in DLCO.
Claim 14
Dependent Claim
60 words
9 . A method of treating low carbon monoxide diffusing capacity of a lung (DLCO) in a patient comprising: measuring an initial DLCO; comparing the initial DLCO to a threshold DLCO; and if the initial DLCO is higher than the threshold DLCO, blocking fluid flow into one or more regions of the lung sufficiently to achieve an increase in DLCO.
Claim 15
Dependent Claim
45 words
10 . A method of treating low carbon monoxide diffusing capacity of a lung (DLCO) in a patient comprising blocking fluid flow into one or more regions of the lung to achieve an increase in DLCO without collapsing or removing the regions of the lung.
Claim 16
Dependent Claim
45 words
10 . A method of treating low carbon monoxide diffusing capacity of a lung (DLCO) in a patient comprising blocking fluid flow into one or more regions of the lung to achieve an increase in DLCO without collapsing or removing the regions of the lung.
Claim 17
Dependent Claim
51 words
11 . A method of treating tuberculosis, comprising: bronchially isolating a lung region to reduce the delivery of oxygen to the lung region and deprive M. tuberculosis bacillus of oxygen in the lung region; and in combination with bronchially isolating the lung region, administering a chemotherapeutic drug to the lung region.
Claim 18
Dependent Claim
51 words
11 . A method of treating tuberculosis, comprising: bronchially isolating a lung region to reduce the delivery of oxygen to the lung region and deprive M. tuberculosis bacillus of oxygen in the lung region; and in combination with bronchially isolating the lung region, administering a chemotherapeutic drug to the lung region.
Claim 19
Dependent Claim
16 words
12 . The method of claim 12 , wherein the chemotherapeutic drug comprises isoniazid or rifampin.
Claim 20
Dependent Claim
33 words
13 . The method of claim 12 , wherein bronchially isolating a lung region comprises implanting one or more bronchial isolation devices into a bronchial passageway that feeds fluid to the lung region.
Claim 21
Dependent Claim
38 words
14 . The method of claim 12 , wherein the bronchial isolation device comprises a one-way valve device that prevent gas from flowing in an inhalation direction and permits gas and mucus to flow in an exhalation direction.
Claim 22
Dependent Claim
44 words
15 . A method of treating an air leak in a lung of a patient, comprising: identifying at least one bronchial passageway that provides airflow to a region of the lung that contains the air leak; blocking fluid flow through the identified bronchial passageway.
Claim 23
Dependent Claim
44 words
15 . A method of treating an air leak in a lung of a patient, comprising: identifying at least one bronchial passageway that provides airflow to a region of the lung that contains the air leak; blocking fluid flow through the identified bronchial passageway.
Claim 24
Dependent Claim
40 words
16 . The method of claim 15 , wherein blocking fluid flow through the identified bronchial passageway comprises implanting one or more bronchial isolation devices into at least one bronchial passageway that provides airflow to the region of the lung.
Claim 25
Dependent Claim
17 words
17 . The method of claim 16 , wherein the bronchial isolation device comprises a one-way valve.
Claim 26
Dependent Claim
35 words
18 . The method of claim 15 , wherein blocking fluid flow through the identified bronchial passageway comprises blocking fluid flow through a plurality bronchial passageways that provides airflow to the region of the lung.
Claim 27
Dependent Claim
51 words
19 . The method of claim 15 , wherein identifying at least one bronchial passageway comprises using a balloon catheter to successively block airflow through bronchial passageways that provide airflow to the region of the lung until an indication is observed that air is no longer flowing through the chest drain.
Claim 28
Dependent Claim
38 words
20 . The method of claim 15 , wherein identifying at least one bronchial passageway comprises: injecting a visible dye into a pleural space of the lung; monitoring the bronchial passageways of the lung for expectoration of dye.
Claim 29
Dependent Claim
18 words
21 . The method of claim 20 , wherein the monitoring step is performed while the patient coughs.
Claim 30
Dependent Claim
49 words
22 . The method of claim 15 , wherein identifying at least one bronchial passageway comprises: injecting a radiographic contrast into a pleural space of the lung; monitoring movement of the contrast through the lung with fluoroscopy or on CT scan during cough and normal breathing of the patient.
References Cited (Backward Citations)
US2981254A
Cited
US3667069A
Cited
US3657744A
Cited
US3788327A
Cited
US3874388A
Cited
US4014318A
Cited
US4086665A
Cited
US4250873A
Cited
US4212463A
Cited
US4382442A
Cited
US4850999A
Cited
US4808183A
Cited
US4819664A
Cited
US4732152A
Cited
US4759758A
Cited
US4832680A
Cited
US4795449A
Cited
US4934999A
Cited
US4830003A
Cited
US5413599A
Cited
US4990151A
Cited
US4846836A
Cited
US5116564A
Cited
US5500014A
Cited
US5411552A
Cited
US6168614B1
Cited
US5116360A
Cited
US5123919A
Cited
US6077291A
Cited
US5382261A
Cited
US5409019A
Cited
US5411507A
Cited
US6558318B1
Cited
US5306234A
Cited
US5486154A
Cited
US5392775A
Cited
US5499995A
Cited
US5499995C1
Cited
US5417226A
Cited
US5522881A
Cited
US5598453A
Cited
US5755770A
Cited
US6022312A
Cited
US6190381B1
Cited
US6068638A
Cited
US6355014B1
Cited
US6027525A
Cited
US5891195A
Cited
US5855587A
Cited
US5855601A
Cited
US6183520B1
Cited
US6027508A
Cited
US6338728B1
Cited
US6200333B1
Cited
US6245102B1
Cited
US5855597A
Cited
US5868779A
Cited
US6366801B1
Cited
US20020077696A1
Cited
US6699231B1
Cited
US5910144A
Cited
US6068635A
Cited
US6009614A
Cited
US6240615B1
Cited
US6174323B1
Cited
US6020380A
Cited
US6051022A
Cited
US6206918B1
Cited
US6234996B1
Cited
US6878141B1
Cited
US20020062120A1
Cited
US6247471B1
Cited
US6402754B1
Cited
US6398775B1
Cited
US20020077593A1
Cited
US6510846B1
Cited
US20040016435A1
Cited
US20030075169A1
Cited
US20050051163A1
Cited
US6840243B2
Cited
US6694979B2
Cited
US20030070683A1
Cited
US6679264B1
Cited
US20030075170A1
Cited
US20020007831A1
Cited
US20020026233A1
Cited
US6527761B1
Cited
US20040055606A1
Cited
US20030018309A1
Cited
US20030018344A1
Cited
US20030018327A1
Cited
US20030024527A1
Cited
US20030051733A1
Cited
US20030050648A1
Cited
US20030070682A1
Cited
US20030083671A1
Cited
US20050066974A1
Cited
US20040037250A1
Cited
US20050016530A1
Cited
US20050137714A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.